MedTrace Logo

A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors

NCT05886374 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2023-07-21

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-415S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

DRUG

HMPL-415S1

HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Bin Yang · Hutchison Medipharma Limited

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2025-05-31
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05886374 on ClinicalTrials.gov